Osaka, Japan

Shintaro Nishimura


Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 70(Granted Patents)


Location History:

  • Settsu, JP (1989 - 2002)
  • Osaka, JP (1998 - 2008)
  • Tokyo, JP (2011)

Company Filing History:


Years Active: 1989-2011

Loading Chart...
9 patents (USPTO):Explore Patents

Title: Shintaro Nishimura: Innovator in Biochemical Research

Introduction

Shintaro Nishimura is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biochemical research, holding a total of nine patents. His work primarily focuses on innovations that enhance medical imaging and therapeutic methods.

Latest Patents

Nishimura's latest patents include a novel O-labeled monosaccharide that is useful for positron emission tomography (PET) and its production method. Additionally, he has developed methods for evaluating phosphatase inhibitors. This invention identifies specific clones that suppress CREB activation and provides evaluation methods using these genes and proteins. The proteins discovered in this research have been found to enhance cell damage, making them potential agents for inhibiting CREB dephosphorylation and for treating memory and neurodegenerative disorders.

Career Highlights

Throughout his career, Nishimura has worked with notable companies, including Fujisawa Pharmaceutical Company, Ltd. His innovative work has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

Nishimura has collaborated with esteemed colleagues such as Nobuyoshi Yasuda and Takao Takaya, contributing to the advancement of research in his field.

Conclusion

Shintaro Nishimura's contributions to biochemical research and his innovative patents highlight his role as a leading inventor in the industry. His work continues to pave the way for advancements in medical technology and therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…